Accuray Incorporated

Day range

$0.12 – $0.13

Open

$0.13

Prev close

$0.13

Volume

1.46M

Market cap

$15.54M

Shares out

119.56M

P/E

—

P/S

0.04

P/B

0.37

P/FCF

—

ROE

-118.0%

ROA

-11.1%

Debt/Equity

3.55

Div yield

0.00%

As of Oct 23, 2026

• Director departureOct 13, 2026

  On October 8, 2026, Mika Nishimura, a Class II director of Accuray Incorporated, informed the Company's Board of Directors of her intention not to stand for re-election at the Company's 2026 annual meeting of stockholders to be held in November 2026. Ms. Nishimura will continue to serve as a director and Chairperson of the Compensation Committee of the Board until the conclusion of the Annual Meeting; her decision is not due to any disagreement with the Company or the Board, or any matter relating to the Company's operations, policies or practices.

• Director appointmentOct 6, 2026

  On October 5, 2026, the Board of Directors ... appointed Richard A. Meier to the Board as a Class II director, with a term expiring at the Company's 2026 annual meeting of stockholders. Mr. Meier was also appointed to the Compensation Committee of the Board on the same date.

• Investor presentationAug 19, 2026

  Spokespersons of the Company plan to present the information in the presentation attached hereto as Exhibit 99.2 to analysts and investors from time to time on or after August 19, 2026. The presentation will be available on the Company's Investor Relations website at: http://investors.accuray.com.

• Listing deficiency noticeAug 6, 2026

  In accordance with Nasdaq rules, the Company has also been granted an additional 180 day period, or until February 1, 2027, to demonstrate compliance with the $1.00 bid price requirement of The NASDAQ Capital Market.

• Private placementJul 29, 2026

  The Company has agreed to issue shares of Series A Preferred Stock and has issued the Warrants. This issuance and sale of the Series A Preferred Stock and the Warrants is exempt from registration under the Securities Act of 1933, as amended (the 'Securities Act'), pursuant to Section 4(a)(2) of the Securities Act. Each Investor represented to the Company that it is an 'accredited investor' as defined in Rule 501 of the Securities Act.

Days to cover

1.0

Short interest

7.39M

Avg volume

35.22M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Oncology Imaging AI: From Experimental to Fast-Scaling Market.
  positiveGlobeNewswire Inc.· Dec 17, 2025
• Robotic Radiotherapy Market Size to Reach USD 3.18 Billion by 2032; Surging Development in Technology Augment Market Expansion Globally – SNS Insider
  positiveGlobeNewswire Inc.· Dec 5, 2025
• Radiotherapy Market Size Expected to Surpass USD 14.76 Billion by 2034
  positiveGlobeNewswire Inc.· Nov 26, 2025
• AI and Robots in Surgery: 3 Stocks Positioned for the Next Medical Revolution
  neutralInvesting.com· Sep 8, 2025
• Accuray Q4 Revenue Hits $128 Million
  neutralThe Motley Fool· Aug 14, 2025